UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2020-01, Vol.31 (1), p.17-29

2020

Volltextzugriff (PDF)

Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2013-10, Vol.24 Suppl 6, p.vi144-vi148

2013

Volltextzugriff (PDF)

Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study

Bone marrow transplantation (Basingstoke), 2017-02, Vol.52 (2), p.216-221

2017

Volltextzugriff (PDF)

Targeting of B‐cell receptor signalling in B‐cell malignancies

Journal of internal medicine, 2017-11, Vol.282 (5), p.415-428

2017

Volltextzugriff (PDF)

ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma

Annals of oncology, 2013-04, Vol.24 (4), p.857-877

2013

Volltextzugriff (PDF)

Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study

Leukemia, 2018-08, Vol.32 (8), p.1799-1803

2018

Volltextzugriff (PDF)

Maintenance therapy following induction chemoimmunotherapy in patients with diffuse large B-cell lymphoma: current perspective

Annals of oncology, 2017-11, Vol.28 (11), p.2680-2690

2017

Volltextzugriff (PDF)

FDG-PET–driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study

Blood, 2017-09, Vol.130 (11), p.1315-1326

2017

Volltextzugriff (PDF)

Non-Hodgkin’s lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome

Annals of oncology, 2008-04, Vol.19 (4), p.774-779

2008

Volltextzugriff (PDF)

IBRUTINIB PLUS BR OR R‐CHOP IN PREVIOUSLY TREATED PATIENTS WITH FOLLICULAR OR MARGINAL ZONE LYMPHOMA: THE PHASE 3 SELENE STUDY

Hematological oncology, 2023-06, Vol.41 (S2), p.872-874

2023

Volltextzugriff (PDF)

Non-MALT marginal zone lymphomas

Annals of oncology, 2008-06, Vol.19 (suppl-4), p.iv70-iv73

Thieblemont, C.

2008

Volltextzugriff (PDF)

Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria

Leukemia, 2008-03, Vol.22 (3), p.487-495

2008

Volltextzugriff (PDF)

Corrigendum to “Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”: [Annals of Oncology 31 (2020) 17–29]

Annals of oncology, 2023-03, Vol.34 (3), p.325-325

2023

Volltextzugriff (PDF)

SAFETY AND EFFICACY OF ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MAGNOLIA PHASE 2 STUDY)

Hematological oncology, 2021-06, Vol.39 (S2)

2021

Volltextzugriff (PDF)

Matching‐adjusted indirect comparison (MAIC) of zanubrutinib (ZANU) versus ibrutinib (IBRU) in relapsed/refractory marginal zone lymphoma (R/R MZL)

Hematological oncology, 2023-06, Vol.41 (S2), p.388-389

2023

Volltextzugriff (PDF)

Hypometabolism on brain FDG-PET as a marker for neurotoxicity after CAR T-cell therapy: A case report

Revue neurologique, 2022-03, Vol.178 (3), p.282-284

2022

Volltextzugriff (PDF)

RISK STRATIFICATION OF DLBCL WITH MVED2 SCORE USING INTEGRATIVE HOST ADIPOSE DENSITY AND METABOLIC TUMOR CHARACTERISTICS COMPARED TO OTHER INDEXES

Hematological oncology, 2023-06, Vol.41 (S2), p.91-91

2023

Volltextzugriff (PDF)

GAPDH enhances the aggressiveness and the vascularization of non-Hodgkin’s B lymphomas via NF-κB-dependent induction of HIF-1α

Leukemia, 2015-05, Vol.29 (5), p.1163-1176

2015

Volltextzugriff (PDF)

PB2073: LACK OF AGREEMENT ON EVENT‐FREE SURVIVAL DEFINITION IN MARGINAL ZONE LYMPHOMA

HemaSphere, 2022-06, Vol.6 (Suppl), p.1944-1945

2022

Volltextzugriff (PDF)

Cause of death and prognosis of patients (pts) with primary refractory disease, and prognosis of pts reaching PFS24: Descriptive analysis of POLARIX

Hematological oncology, 2023-06, Vol.41 (S2), p.432-433

2023

Volltextzugriff (PDF)

Efficacy of Subcutaneous Epcoritamab versus Axi‐cel in R/R DLBCL CAR T‐Naive and CAR T‐eligible patients: An Indirect Comparison

Hematological oncology, 2023-06, Vol.41 (S2), p.453-454

2023

Volltextzugriff (PDF)

Prognostic Value of Lymphopenia and Total Metabolic Tumor Volume in Diffuse Large Cell Lymphoma of B Phenotype in the RT3 and REMARC trials—A LYSA retrospective analysis

Hematological oncology, 2023-06, Vol.41 (S2), p.346-347

2023

Volltextzugriff (PDF)

Evaluation of ctDNA in a phase I/II trial in relapsed or refractory large B‐cell lymphoma of epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T‐cell–engaging antibody

Hematological oncology, 2023-06, Vol.41 (S2), p.326-328

2023

Volltextzugriff (PDF)

1 – 25 von 508

Suche als RSS-Feed

Aktive Filter

ThemaAged

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(376)
Mit Volltextzugriff
(411)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(318)
Französisch
(195)
Deutsch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(112)
Life Sciences & Biomedicine
(90)
Humans
(81)
Lymphoma
(73)
Hematology
(57)
Oncology
(45)
Life Sciences
(34)
Biological And Medical Sciences
(33)
Medical Sciences
(32)
Hematologic And Hematopoietic Diseases
(26)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(25)
Female
(24)
Physical Sciences
(23)
Prognosis
(22)
Animals
(21)
B-Cell Lymphoma
(21)
Male
(20)
Middle Aged
(19)
Cancer
(18)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(17)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)

Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study

Targeting of B‐cell receptor signalling in B‐cell malignancies

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)

ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma

Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study

Maintenance therapy following induction chemoimmunotherapy in patients with diffuse large B-cell lymphoma: current perspective

FDG-PET–driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study

Non-Hodgkin’s lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome

IBRUTINIB PLUS BR OR R‐CHOP IN PREVIOUSLY TREATED PATIENTS WITH FOLLICULAR OR MARGINAL ZONE LYMPHOMA: THE PHASE 3 SELENE STUDY

Non-MALT marginal zone lymphomas

Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria

Corrigendum to “Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”: [Annals of Oncology 31 (2020) 17–29]

SAFETY AND EFFICACY OF ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MAGNOLIA PHASE 2 STUDY)

Matching‐adjusted indirect comparison (MAIC) of zanubrutinib (ZANU) versus ibrutinib (IBRU) in relapsed/refractory marginal zone lymphoma (R/R MZL)

Hypometabolism on brain FDG-PET as a marker for neurotoxicity after CAR T-cell therapy: A case report

RISK STRATIFICATION OF DLBCL WITH MVED2 SCORE USING INTEGRATIVE HOST ADIPOSE DENSITY AND METABOLIC TUMOR CHARACTERISTICS COMPARED TO OTHER INDEXES

GAPDH enhances the aggressiveness and the vascularization of non-Hodgkin’s B lymphomas via NF-κB-dependent induction of HIF-1α

PB2073: LACK OF AGREEMENT ON EVENT‐FREE SURVIVAL DEFINITION IN MARGINAL ZONE LYMPHOMA

Cause of death and prognosis of patients (pts) with primary refractory disease, and prognosis of pts reaching PFS24: Descriptive analysis of POLARIX

Efficacy of Subcutaneous Epcoritamab versus Axi‐cel in R/R DLBCL CAR T‐Naive and CAR T‐eligible patients: An Indirect Comparison

Prognostic Value of Lymphopenia and Total Metabolic Tumor Volume in Diffuse Large Cell Lymphoma of B Phenotype in the RT3 and REMARC trials—A LYSA retrospective analysis

Evaluation of ctDNA in a phase I/II trial in relapsed or refractory large B‐cell lymphoma of epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T‐cell–engaging antibody

Aktive Filter

Suchergebnisse filtern